<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Factor IX, recombinant human with albumin fusion: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Factor IX, recombinant human with albumin fusion: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Factor IX, recombinant human with albumin fusion: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="107446" href="/d/html/107446.html" rel="external">see "Factor IX, recombinant human with albumin fusion: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="130882" href="/d/html/130882.html" rel="external">see "Factor IX, recombinant human with albumin fusion: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F46305844"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Idelvion</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F53638406"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Idelvion</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F46245252"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antihemophilic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F46360597"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="98495059-e110-44f0-ad91-ba0bd4d84e5d">Hemophilia B, without inhibitors</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemophilia B, without inhibitors:</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Contains <b>only factor IX</b>. Therefore, <b>NOT INDICATED</b> for replacement therapy of other clotting factors besides factor IX, hemophilia A patients with inhibitors to factor VIII, reversal of anticoagulation due to vitamin K antagonists or other anticoagulants, or bleeding due to low levels of liver-dependent clotting factors.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Treatment and control of bleeding episodes or perioperative management:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Intermittent IV bolus dosing: </i>IV:</b> Utilize steps 1 to 4 to determine intermittent bolus dosing strategy. Individualize dosage based on coagulation studies performed prior to treatment and at regular intervals during treatment.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Step 1:</b> Identify product-specific in vivo recovery (IVR) for dosing calculations (<b>Note:</b> IVR indicates the expected increase in factor IX level, which occurs with 1 unit/kg of factor IX product administration):</p>
<p style="text-indent:-2em;margin-left:10em;">Idelvion IVR: 1.3.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Step 2:</b> Determine desired factor IX peak level and anticipated duration of therapy based on the World Federation of Hemophilia (WFH) treatment recommendations; see table. Selection of the lower-dose practice pattern requires closer observation with the potential for requiring escalation to higher doses based on clinical response.</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption>
<b>Factor IX </b>
<b>(Recombinant Albumin Fusion Protein) WFH Treatment Recommendations<sup>a</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center" rowspan="2">
<p style="text-indent:0em;">Type of hemorrhage or surgery</p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;">Lower dose practice pattern</p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;">Higher dose practice pattern</p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">Desired peak factor IX level (units/dL)</p></th>
<th align="center">
<p style="text-indent:0em;">Treatment duration (days)</p></th>
<th align="center">
<p style="text-indent:0em;">Desired peak factor IX level (units/dL)</p></th>
<th align="center">
<p style="text-indent:0em;">Treatment duration (days)</p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>WFH = World Hemophilia Federation; (WFH [Srivastava 2020]).</p>
<p style="text-indent:0em;text-align:left;">
<sup>b</sup> May be longer if response is inadequate.</p>
<p style="text-indent:0em;text-align:left;">
<sup>c </sup>Sometimes longer as secondary prophylaxis during physical therapy.</p>
<p style="text-indent:0em;text-align:left;">
<sup>d</sup> A single dose may be sufficient for some joint bleeds; determine need for additional doses based on clinical response.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Joint</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2<sup>b,d</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2<sup>b,d</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Superficial muscle/no neurovascular compromise (except iliopsoas)</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 to 3<sup>b</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 to 3<sup>b</sup></p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Iliopsoas or deep muscle with neurovascular injury or substantial blood loss</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15 to 30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5<sup>c</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5<sup>c</sup></p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Intracranial</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 7</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8 to 21</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8 to 14</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Throat and neck</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 7</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8 to 14</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>GI</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7 to 14</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Renal</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15 to 30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Deep laceration</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15 to 30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 to 7</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Surgery (major)</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Pre-op</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 to 70</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;text-align:left;">Post-op</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 6</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 6</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7 to 14</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7 to 14</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Surgery (minor)</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Pre-op</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Post-op</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 5</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 5</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:8em;">
<b>Step 3:</b> Calculate dose using IVR from step 1, desired peak factor IX level from step 2, and the following equation:</p>
<p style="text-indent:-2em;margin-left:10em;">Factor IX units required = ([desired peak factor IX level − patient's baseline factor IX level] × body weight [kg])/IVR</p>
<p style="text-indent:-2em;margin-left:12em;">(<b>Note:</b> Factor IX units are in units/dL.)</p>
<p style="text-indent:-2em;margin-left:10em;">Example (Idelvion) for 50 kg patient with desired peak factor IX level of 35 units/dL, baseline factor IX level of 5 units/dL, IVR = 1.3:</p>
<p style="text-indent:-2em;margin-left:10em;">Factor IX units required = ([35 units/dL − 5 units/dL] × 50 kg) ⁄ 1.3 = 1,154 units factor IX</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Step 4:</b> Determine need for repeat dosing based on manufacturer’s recommended frequency of repeat dosing. <b>Note</b>
<b>:</b> Frequency of administration must also take into consideration subsequent factor IX activity measurements and clinical response.</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption>
<b>Factor IX (Recombinant Albumin Fusion Protein) Administration Frequency According to Clinical Scenario</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col/>
</colgroup><thead>
<tr>
<th align="center" rowspan="2">
<p style="text-indent:0em;">Product</p></th>
<th align="center" colspan="3">
<p style="text-indent:0em;text-align:center;">Bleeding event</p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;">Surgery</p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">Minor severity</p></th>
<th align="center">
<p style="text-indent:0em;">Moderate severity</p></th>
<th align="center">
<p style="text-indent:0em;">Major severity</p></th>
<th align="center">
<p style="text-indent:0em;">Minor bleeding risk</p></th>
<th align="left">
<p style="text-indent:0em;">Major bleeding risk</p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">Idelvion</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Every 48 to 72 hours</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Every 48 to 72 hours</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Every 48 to 72 hours</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Every 48 to 72 hours</p></td>
<td align="left">
<p style="text-indent:0em;">Every 48 to 72 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with moderate/severe hemophilia B without inhibitors:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 25 to 40 units/kg once every 7 days; if well controlled, may switch to 50 to 75 units/kg once every 14 days. Dosing should be tailored to ensure trough factor IX levels of ≥1% and preferably ≥3 % to 5% are achieved, but prophylaxis targets should be tailored to individual level of activity, lifestyle, and pharmacokinetics. Dose escalation should be considered for patients adherent to prescribed prophylaxis but still experiencing breakthrough bleeding events (WFH [Srivastava 2020]).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990460"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturers labeling.</p></div>
<div class="block doha drugH1Div" id="F50987693"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturers labeling; use with caution in patients with hepatic disease.</p></div>
<div class="block doo drugH1Div" id="F55978600"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">There are insufficient data to recommend the best dosing weight to use in patients with obesity. Dose adjustments should ultimately be made based on individual patient response to therapy. Due to the paucity of data, refer to institutional protocols. Refer to adult dosing for indication-specific dosing.</p></div>
<div class="block doe drugH1Div" id="F46360601"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F46361337"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="130882" href="/d/html/130882.html" rel="external">see "Factor IX, recombinant human with albumin fusion: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9d3c8dbc-ec3d-4b92-8b0e-9f550b04753f">Hemophilia B</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemophilia B (congenital factor IX deficiency):</b> Individualize dosage based on clinical response and factor IX activity evaluated at baseline and at regular intervals during treatment. In general, administration of factor IX (recombinant [albumin fusion protein]) 1 unit/kg will increase circulating factor IX levels by 1 units/dL in infants and children &lt;12 years and by 1.3 units/dL in children ≥12 years and adolescents.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>General dosing recommendations: Note:</b> Dose and duration of treatment depends on the severity of factor IX deficiency, location and extent of bleeding, and the patient's clinical condition, age, and recovery of factor IX. Adjust dosing regimen based on individual response.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Formula for units required to raise blood level:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Number of factor IX units required = patient weight (in kg) x desired factor IX level increase (as % or units/dL) x reciprocal of recovery (as units/kg per units/dL)</p>
<p style="text-indent:-2em;margin-left:10em;">Reciprocal of recovery (as units/kg per units/dL):</p>
<p style="text-indent:-2em;margin-left:12em;">Infants and Children &lt;12 years: 1</p>
<p style="text-indent:-2em;margin-left:12em;">Children ≥12 years and Adolescents: ~0.8</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>On-demand control and prevention of bleeding episodes:</b> Infants, Children, and Adolescents: IV:</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Type of Bleeding</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Desired Factor IX Level</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Frequency</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Duration</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">
<b>
<i>Minor or moderate</i></b>
<b>
<i>bleeding </i></b>(eg, uncomplicated hemarthrosis, muscle bleeding [except iliopsoas] or oral bleeding)</p></td>
<td align="center">
<p style="text-indent:0em;">30 to 60 units/dL</p></td>
<td align="center">
<p style="text-indent:0em;">48 to 72 hours</p></td>
<td align="center">
<p style="text-indent:0em;">At least 1 day, until bleeding stops and healing is achieved. Single dose should be sufficient for majority of bleeds.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<b>
<i>Major bleeding</i></b> (eg, life or limb threatening hemorrhage, deep muscle bleeding, including iliopsoas, intracranial, retropharyngeal)</p></td>
<td align="center">
<p style="text-indent:0em;">60 to 100 units/dL</p></td>
<td align="center">
<p style="text-indent:0em;">48 to 72 hours</p></td>
<td align="center">
<p style="text-indent:0em;">7 to 14 days, or until bleeding stops and healing is achieved. Maintenance dose weekly.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<b>Perioperative management of bleeding: </b>Infants, Children, and Adolescents: IV:</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Type of Surgery</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Desired Factor IX Level</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Frequency</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Duration</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">
<b>
<i>Minor Surgery</i></b> (including uncomplicated tooth extraction)</p></td>
<td align="center">
<p style="text-indent:0em;">50 to 80 units/dL</p></td>
<td align="center">
<p style="text-indent:0em;">48 to 72 hours</p></td>
<td align="center">
<p style="text-indent:0em;">At least 1 day or until bleeding stops and healing is achieved. Single dose should be sufficient for majority of minor surgeries.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<b>
<i>Major Surgery</i></b> (including intracranial, pharyngeal, retropharyngeal, retroperitoneal)</p></td>
<td align="center">
<p style="text-indent:0em;">60 to 100 units/dL (initial level)</p></td>
<td align="center">
<p style="text-indent:0em;">48 to 72 hours</p></td>
<td align="center">
<p style="text-indent:0em;">7 to 14 days, or until bleeding stops and healing is achieved. Repeat dose every 48 to 72 hours for the first week or until healing is achieved. Maintenance dose 1 to 2 times per week.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<b>Routine prophylaxis:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children &lt;12 years: IV: 40 to 55 units/kg/dose once every 7 days.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents: IV: 25 to 40 units/kg/dose once every 7 days; if well controlled, may switch to 50 to 75 units/kg/dose once every 14 days.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51109864"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51109865"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution in patients with hepatic disease.</p></div>
<div class="block adr drugH1Div" id="F46364576"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in previously treated patients.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Nervous system: Dizziness (2%), headache (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Eczema, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Factor IX inhibitor in hemophilia B</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (neutralizing)</p></div>
<div class="block coi drugH1Div" id="F46245255"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Life-threatening hypersensitivity to factor IX (recombinant [albumin fusion protein]) or any component of the formulation including hamster proteins</p></div>
<div class="block war drugH1Div" id="F46360568"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antibody formation: Neutralizing antibodies (inhibitors) to factor IX may develop; monitor for development of antibodies with lab tests and clinical observation. Perform assay to measure factor IX inhibitor concentration if expected plasma factor IX activity levels are not attained or if bleeding is not controlled at an appropriate dose. Patients with factor IX inhibitors are at increased risk for severe hypersensitivity reactions or anaphylaxis upon re-exposure. Evaluate patients experiencing allergic reactions for the presence of an inhibitor. Monitor patients with inhibitors for signs/symptoms of acute hypersensitivity, particularly in the early phases of exposure.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions (including anaphylaxis) may occur; early signs include angioedema, chest tightness, hypotension, urticarial (generalized) wheezing, and dyspnea. Discontinue immediately (and manage appropriately) if symptoms of hypersensitivity occur. Contains trace amounts of Chinese hamster ovary proteins; hypersensitivity to these proteins may develop.</p>
<p style="text-indent:-2em;margin-left:4em;">• Nephrotic syndrome: Nephrotic syndrome has been reported following attempted immune tolerance induction in hemophilia B patient with factor IX inhibitors and a history of allergic reactions. Safety and efficacy in this situation have not been established.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thromboembolic events: Thromboembolism (eg, pulmonary embolism, venous/arterial thrombosis) may occur. Monitor for early signs of thromboembolism and coagulopathy in patients with hepatic disease, fibrinolysis, perioperative status, or risk factors for thromboembolic events or disseminated intravascular coagulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer’s labeling.</p></div>
<div class="block foc drugH1Div" id="F46305845"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Idelvion: 250 units (1 ea); 500 units (1 ea); 1000 units (1 ea); 2000 units (1 ea) [contains hamster protein, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Idelvion: 3500 units (1 ea) [contains hamster protein, polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F46305843"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F46312631"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Idelvion Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 unit (Price provided is per AHF Unit): $6.22</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 unit (Price provided is per AHF Unit): $6.22</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 unit (Price provided is per AHF Unit): $6.22</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2000 unit (Price provided is per AHF Unit): $6.22</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3500 unit (Price provided is per AHF Unit): $6.22</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F53638407"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Idelvion: 1000 units (1 ea) [contains hamster protein, polysorbate 80]</p></div>
<div class="block adm drugH1Div" id="F46360605"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: For IV injection only. Do not use if particulate matter or discoloration is observed. Adjust infusion rate to comfort level of the patient, not exceeding 10 mL/minute. Administer at room temperature and within 4 hours of reconstitution.</p></div>
<div class="block admp drugH1Div" id="F52614642"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV: For IV administration only. Do not use if particulate matter or discoloration is observed. Administer at room temperature and within 4 hours of reconstitution through a separate line; do not mix with other drugs. Adjust infusion rate to comfort level of the patient, not exceeding 10 mL/minute. With patients who have had allergic reactions during factor IX infusion, administration of antihistamine prior to infusion may be necessary (WFH [Srivastava 2020]).</p></div>
<div class="block use drugH1Div" id="F46245254"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemophilia B: </b>Prevention and on-demand control of bleeding episodes in adults and children; perioperative management of bleeding in adults and children; routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children.</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Not indicated for immune tolerance induction in patients with hemophilia B.</p></div>
<div class="block mst drugH1Div" id="F46360563"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Factor IX (Recombinant [albumin fusion protein]) may be confused with other factor IX products</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F46283953"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F46283950"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F46360566"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Pregnant carriers of hemophilia B may have an increased bleeding risk following abortion, invasive procedures, spontaneous miscarriage, termination of pregnancy, and delivery; close surveillance is recommended. Factor IX levels should be monitored at the first antenatal visit, once or twice during the third trimester, prior to surgical or invasive procedures, and at delivery. Although factor IX levels remain stable during pregnancy, factor IX replacement is recommended if concentrations are &lt;50 units/dL and any of the following occur: need for invasive procedures (including delivery), spontaneous miscarriage, insertion and removal of epidural catheters, or active bleeding. Hemostatic factor IX concentrations should be maintained for at least 3 to 5 days following invasive procedures or postpartum. If replacement with a factor IX concentrate is indicated to increase factor IX during pregnancy, a recombinant product is preferred (NHF 2017; RCOG [Pavord 2017]; WFH [Srivastava 2020]).</p></div>
<div class="block brc drugH1Div" id="F46360567"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if factor IX (recombinant) is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F46360607"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Monitoring assay selection: </b>For Idelvion, the World Federation of Hemophilia recommends use of an aPTT-based one-stage factor IX activity assay with validated reagents, calibrated with a plasma standard traceable to a WHO international standard. <b>Note:</b> One-stage FIX assays with ellagic acid activator reagent Actin FS or kaolin activator reagent CK Prest significantly <i>underestimate</i> true Idelvion FIX activity and should not be used. One-stage FIX assays with the ellagic acid activator SynthAFax reagent or chromogenic FIX assays significantly <i>overestimate</i> true Idelvion FIX activity and should not be used (WFH [Srivastava 2020]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Monitoring frequency</b>: During treatment of an acute bleeding event or in the perioperative setting using intermittent bolus administration, factor IX levels should be measured at baseline and as peaks 15 to 30 minutes after infusion to assess target level achievement. The frequency of peak factor IX activity monitoring during active treatment depends on the indication, clinical response, and treatment day. Measurement of FIX trough levels may aid in calculation of subsequent doses (WFH [Srivastava 2020]).</p>
<p style="text-indent:-2em;margin-left:2em;">For long-term bleeding prophylaxis, trough factor IX measurements should be obtained to tailor prophylaxis regimens, with the goal of achieving factor IX troughs &gt;3 to 5 units/dL; prophylaxis targets should be tailored to individual level of activity, lifestyle, and pharmacokinetics.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Additional monitoring considerations: </b>Heart rate and BP before and during IV administration, signs of hypersensitivity reactions (which may be an early sign of inhibitor development), hemoglobin/hematocrit, and signs and symptoms of intravascular hemolysis. Lower than expected factor IX recovery or reduced half-life are early signs of inhibitor formation.</p>
<p style="text-indent:-2em;margin-left:2em;">Lower than expected factor IX recovery or reduced half-life are early signs of inhibitor formation.</p></div>
<div class="block rer drugH1Div" id="F55978608"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Classification of hemophilia; normal is defined as 100% factor IX (WFH [Srivastava 2020]).</p>
<p style="text-indent:-2em;margin-left:2em;">Severe: Factor level &lt;1% of normal.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate: Factor level 1% to 5% of normal.</p>
<p style="text-indent:-2em;margin-left:2em;">Mild: Factor level 5% to &lt;40% of normal.</p></div>
<div class="block pha drugH1Div" id="F46360572"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Factor IX (recombinant [albumin fusion protein]) is a recombinant protein that temporarily replaces the missing coagulation factor IX needed for effective hemostasis in patients with hemophilia B. Factor IX (recombinant [albumin fusion protein]) is comprised of genetically fused recombinant coagulation factor IX and recombinant albumin. Fusion with recombinant albumin extends the half-life of factor IX.</p></div>
<div class="block phk drugH1Div" id="F46360574"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>ss</sub>:</p>
<p style="text-indent:-2em;margin-left:4em;">Pediatric patients:</p>
<p style="text-indent:-2em;margin-left:6em;">0 to &lt;6 years: 1.42 dL/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">6 to &lt;12 years: 1.32 dL/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">12 to &lt;18 years: 1.16 dL/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 0.86 to 1.2 dL/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Pediatric patients:</p>
<p style="text-indent:-2em;margin-left:6em;">0 to &lt;6 years: 90 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">6 to &lt;12 years: 93 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">12 to &lt;18 years: 87 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 104 to 118 hours.</p></div>
<div class="block phksp drugH1Div" id="F51154127"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: Compared to adults, incremental rIX-FP recovery appeared to be slightly lower and body weight-adjusted clearance appeared to be higher. Children may have higher Factor IX body weight-adjusted clearance, shorter half-life, and lower recovery. Higher dose per kilogram body weight or more frequent dosing may be needed in these patients.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F50663218"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Idelvion</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Idelvion</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Idelvion</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Idelvion</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Idelvion</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Idelvion</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Idelvion</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Idelvion</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Idelvion</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Idelvion</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Idelvion</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Idelvion</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Idelvion</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Idelvion</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Idelvian</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Idelvion</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Idelvion</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Idelvion</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Idelvion</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Idelvion</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Idelvion</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Idelvion</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Idelvion</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-with-albumin-fusion-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-with-albumin-fusion-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Idelvion (factor IX [recombinant (albumin fusion protein)]) [prescribing information]. Kankakee, IL: CSL Behring LLC; July 2021.</div>
</li>
<li>
<div class="reference">
                  Idelvion (factor IX [recombinant (albumin fusion protein)]) [prescribing information]. Kankakee, IL: CSL Behring LLC; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-with-albumin-fusion-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-with-albumin-fusion-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  National Hemophilia Foundation (NHF). Medical and Scientific Advisory Council (MASAC) guidelines for perinatal management of women with bleeding disorders and carriers of hemophilia A and B (MASAC document 251). https://www.hemophilia.org/node/3660. Published September 17, 2017. Accessed June 7, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28447403">
<a name="28447403"></a>Pavord S, Rayment R, Madan B, et al; for the Royal College of Obstetricians and Gynaecologists. Management of inherited bleeding disorders in pregnancy: Green-top Guideline No. 71 (joint with UKHCDO). <i>BJOG</i>. 2017;124(8):e193–e263. doi: 10.1111/1471-0528.14592.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-with-albumin-fusion-drug-information/abstract-text/28447403/pubmed" id="28447403" target="_blank">28447403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-with-albumin-fusion-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32744769">
<a name="32744769"></a>Srivastava A, Santagostino E, Dougall A, et al; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH guidelines for the management of hemophilia, 3rd edition. <i>Haemophilia</i>. 2020;26(suppl 6):1-158. doi:10.1111/hae.14046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-with-albumin-fusion-drug-information/abstract-text/32744769/pubmed" id="32744769" target="_blank">32744769</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 107193 Version 77.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
